{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T08:59:27Z","timestamp":1790758767072,"version":"4.1.0"},"reference-count":11,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2018,10,30]],"date-time":"2018-10-30T00:00:00Z","timestamp":1540857600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Mult Scler"],"published-print":{"date-parts":[[2019,4]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Dalfampridine extended release (DAL) is a broad-spectrum voltage-gated potassium channel blocker that is indicated in multiple sclerosis to improve the nerve conduction of demyelinated axons. Seizures are a known side effect of DAL, which is contraindicated in patients with a history of epilepsy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>Three cases of multiple sclerosis (MS) with de novo convulsive status epilepticus (CSE) probably related to dalfampridine administration are described.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>No patients had a history of seizures or renal impairment. Biological tests were normal. A brain magnetic resonance imaging (MRI) showed diffuse cortical and subcortical atrophy without active inflammatory lesions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>All three patients presented with CSE that was attributed to DAL and so was discontinued.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>These case reports illustrate that, aside from seizures, de novo CSE is a potential complication of MS patients treated with DAL.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/1352458518790379","type":"journal-article","created":{"date-parts":[[2018,10,30]],"date-time":"2018-10-30T08:37:51Z","timestamp":1540888671000},"page":"618-621","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":5,"title":["De novo convulsive status epilepticus in patients with multiple sclerosis treated with dalfampridine"],"prefix":"10.1177","volume":"25","author":[{"given":"Emilie","family":"Panicucci","sequence":"first","affiliation":[{"name":"Service de Neurologie, CRCSEP, H\u00f4pital Pasteur 2, Nice, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikael","family":"Cohen","sequence":"additional","affiliation":[{"name":"Service de Neurologie, CRCSEP, H\u00f4pital Pasteur 2, Nice, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronique","family":"Bourg","sequence":"additional","affiliation":[{"name":"Service de Neurologie, CRCSEP, H\u00f4pital Pasteur 2, Nice, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanny","family":"Rocher","sequence":"additional","affiliation":[{"name":"Centre r\u00e9gional de Pharmacovigilance, H\u00f4pital Cimiez, Nice, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Thomas","sequence":"additional","affiliation":[{"name":"Service de Neurologie, CRCSEP, H\u00f4pital Pasteur 2, Nice, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Lebrun","sequence":"additional","affiliation":[{"name":"Service de Neurologie, CRCSEP, H\u00f4pital Pasteur 2, Nice, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2018,10,30]]},"reference":[{"key":"bibr1-1352458518790379","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2012.03.007"},{"key":"bibr2-1352458518790379","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60442-6"},{"key":"bibr3-1352458518790379","doi-asserted-by":"publisher","DOI":"10.1002\/ana.22240"},{"key":"bibr4-1352458518790379","doi-asserted-by":"publisher","DOI":"10.2147\/DHPS.S97113"},{"key":"bibr5-1352458518790379","doi-asserted-by":"publisher","DOI":"10.1177\/1352458514563591"},{"key":"bibr6-1352458518790379","doi-asserted-by":"publisher","DOI":"10.1016\/S1059-1311(97)80037-4"},{"key":"bibr7-1352458518790379","doi-asserted-by":"publisher","DOI":"10.2165\/11310900-000000000-00000"},{"key":"bibr8-1352458518790379","doi-asserted-by":"publisher","DOI":"10.1111\/j.1527-3458.2004.tb00029.x"},{"key":"bibr9-1352458518790379","unstructured":"ANSM. ATU Qizenday (rapport de synthese N\u00b02), 12\/09\/2017, REP-017-001. Available at http:\/\/ansm.sante.fr\/content\/download\/110237\/1396599\/version\/2\/file\/ATU-+Rapport-Synthese-1-+Qizenday.pdf"},{"key":"bibr10-1352458518790379","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000154639.35941.21"},{"key":"bibr11-1352458518790379","unstructured":"NDA020235\/S-036; NDA 020882\/S-022; NDA 021129\/S-022: FDA approved labeling text dated03\/01\/2011, Neurontin\n                      \u00ae\n                      (Gabapentin), https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/020235s036,020882s022,021129s022lbl.pdf"}],"container-title":["Multiple Sclerosis Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1352458518790379","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1352458518790379","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1352458518790379","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T03:55:23Z","timestamp":1777694123000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1352458518790379"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,30]]},"references-count":11,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["10.1177\/1352458518790379"],"URL":"https:\/\/doi.org\/10.1177\/1352458518790379","relation":{},"ISSN":["1352-4585","1477-0970"],"issn-type":[{"value":"1352-4585","type":"print"},{"value":"1477-0970","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,30]]}}}